633
Views
10
CrossRef citations to date
0
Altmetric
Review

Points for Consideration for dengue vaccine introduction – recommendations by the Dengue Vaccine Initiative

, , , , &
Pages 529-538 | Received 05 Oct 2015, Accepted 04 Dec 2015, Published online: 06 Jan 2016

References

  • Mahoney R. The introduction of new vaccines into developing countries. V: will we lose a decade or more in the introduction of dengue vaccines to developing countries? Vaccine. 2014;32(8):904–908.
  • Hajjeh RA, Privor-Dumm L, Edmond K, et al. Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience. Vaccine. 2010;28(43):7123–7129.
  • Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299–309.
  • Thomas SJ. Preventing dengue – is the possibility now a reality? N Engl J Med. 2015;372(2):172–173.
  • Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis. 2011;24(5):442–450.
  • Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014;384(9951):1327–1329.
  • Wilder-Smith A, Macary P. Dengue: challenges for policy makers and vaccine developers. Curr Infect Dis Rep. 2014;16(5):404.
  • Ramakrishnan L, Pillai MR, Nair RR. Dengue vaccine development: strategies and challenges. Viral Immunol. 2015;28(2):76–84.
  • Sariol CA, White L. Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front Immunol. 2014;5(452).
  • Wallace D, Canouet V, Garbes P, et al. Challenges in the clinical development of a dengue vaccine. Curr Opin Virol. 2013;3(3):352–356.
  • APDPB, DVI. Points for consideration for first introductions of Dengue Vaccines – the DVI Asia-Pacific Dengue Prevention Board meeting. Dengue Vaccine Initiative;2012.
  • AmDPB, DVI. Points for Consideration for First Introductions of Dengue Vaccines – the DVI Americas Dengue Prevention Board meeting. Dengue Vaccine Initiative;2012.
  • Sabchareon A, W D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–1567.
  • Arya V. An effective dengue vaccine: a glass half full or half empty? Natl Med J India. 2013;26(1):38–39.
  • Rodriguez-Barraquer I, Mier-y-Teran-Romero L, Burke D, et al. Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis. 2013;7(8):e2126.
  • Capeding MR, Tran N, Hadinegoro SR, et al. CYD14 study group. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet (London, England). 2014;384(9951):1358–1365.
  • Villar L, Rivera-Medina D, Arredondo-García JL, et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J. 2013;32(10):1102–1109.
  • APDPB, DVI. Development of dengue vaccines – a review of the status and future considerations, the DVI Asia-Pacific Dengue Prevention Board meeting. Dengue Vaccine Initiative;2014.
  • AmDPB, DVI. Development of dengue vaccines – a review of the status and future considerations, - the DVI Americas Dengue Prevention Board meeting. Dengue Vaccine Initiative;2015.
  • Torresi J, Tapia-Conyer R, Margolis H. Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting. PLoS Negl Trop Dis. 2013;7(9):e2261.
  • Thisyakorn U, Capeding MR, Goh DY, et al. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Rev Vaccines. 2014;13(5):581–587.
  • Tapia-Conyer R, Betancourt-Cravioto M, Saucedo-Martinez R, et al. Strengthening vaccination policies in Latin America: an evidence-based approach. Vaccine. 2013;31(37):3826–3833.
  • Edelman R, Hombach J. ‘Guidelines for the clinical evaluation of dengue vaccines in endemic areas’: summary of a World Health Organization Technical Consultation. Vaccine. 2008;26(33):4113–4119.
  • Lam SK, Burke D, Capeding MR, et al. Preparing for introduction of a dengue vaccine: recommendations from the 1st Dengue v2V Asia-Pacific Meeting. Vaccine. 2011;29(51):9417–9422.
  • Hajjeh R. Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2827–2832.
  • Hyde TB, Dentz H, Wang SA, et al. The impact of new vaccine introduction on immunization and health systems: a review of the published literature. Vaccine. 2012;30(45):6347–6358.
  • Hombach J. Guidelines for clinical trials of dengue vaccine in endemic areas. J Clin Virol. 2009;46(Suppl 2):S7–9.
  • Live Dengue Vaccines Technical Consultation Reporting Group1 B-EA, Schmitz J, Edelman R, Durbin A, et al. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine. 2013;31(23):2603–2609.
  • Douglas DL, DeRoeck DA, Mahoney RT, et al. Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders. PLoS Negl Trop Dis. 2013;7(3):e2127.
  • Thiry GHJ, Constenla D, Carvalho A, et al. New chapter unfolding in the fight against dengue with an unwritten ending. Trans R Soc Trop Med Hyg. 2014;108(10):597–598.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.